Clinical Report: New Marker for Aggressive Prostate Cancer

Overview

Revise to specify that FOXA1 is particularly relevant for small cell carcinoma of the prostate.

Background

Prostate cancer remains a leading cause of cancer-related mortality among men, with significant challenges in diagnosing aggressive forms of the disease. Traditional markers often fail in high-grade or treatment-resistant tumors, necessitating the identification of new biomarkers to improve diagnostic accuracy and patient management.

Data Highlights

Key Findings

• FOXA1 shows high sensitivity for prostate adenocarcinoma.
• FOXA1 is detectable in many cases of small cell carcinoma of the prostate.
• 80% of primary small cell carcinomas retain FOXA1 expression.
• 57% of metastatic small cell carcinoma cases maintain FOXA1 expression despite loss of conventional markers.
• FOXA1 staining may assist in identifying the tissue of origin in diagnostically ambiguous cases.

Clinical Implications

FOXA1 could be integrated into diagnostic panels for prostate cancer, particularly for aggressive and treatment-resistant variants. Its ability to remain detectable when traditional markers are lost may enhance diagnostic accuracy and inform treatment decisions.

Conclusion

The findings suggest that FOXA1 is a promising adjunct marker in the evaluation of aggressive prostate cancers, warranting further validation in clinical practice.

Related Resources & Content

1. The ASCO Post, 2014 -- Prostate Cancer Biomarkers: Improvement in Predicting Clinically Significant Disease
2. The ASCO Post, 2025 -- Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
3. NCCN Clinical Practice Guidelines In Oncology, 2026 -- Prostate Cancer
4. UT MD Anderson, 2023 -- New marker aids diagnosis for aggressive prostate cancer
5. The ASCO Post — Prostate Cancer Biomarkers: Improvement in Predicting Clinically Significant Disease
6. The ASCO Post — New Biomarker Predicts Survival in Advanced Prostate Cancer Related Articles
7. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology - PubMed
8. New marker aids diagnosis for aggressive prostate cancer | UT MD Anderson